Veterinary Practice Valuation Guide: What Your Clinic Is Really Worth

Veterinary practice valuations have gone through a seismic shift over the past decade. Practices that would have sold for 4-5x EBITDA in 2015 are now commanding 8-14x from corporate consolidators. If you own a vet clinic and haven't had it valued in the last three years, whatever number you have in your head is almost certainly wrong — and it could be wrong in either direction.

I've been involved in veterinary M&A since before Mars Petcare acquired VCA for $9.1 billion in 2017, the deal that effectively broke the old pricing paradigm for vet practices. Let me walk you through what actually determines your practice's value in the current market.

The Two Markets for Vet Practices

There are functionally two separate markets operating simultaneously, and they price practices very differently.

Market 1: Individual/Associate Buyers. A veterinarian buying their first practice, typically financed through a bank loan or SBA 7(a). These buyers can afford 3-5x SDE, sometimes up to 6x for a well-run practice in a desirable location. They're constrained by what the business can cash-flow after debt service while still paying them a competitive DVM salary ($120K-$180K depending on geography).

Market 2: Corporate Consolidators. Mars Veterinary Health (which owns VCA, Banfield, and BluePearl), NVA, Pathway Vet Alliance, Thrive Pet Healthcare, and a half-dozen other PE-backed platforms. These buyers routinely pay 8-14x EBITDA for practices that meet their criteria. They can pay more because they're buying at scale, applying corporate overhead efficiencies, and valuing each acquisition as part of a larger portfolio strategy.

The gap between these two markets is enormous. A practice doing $2M in revenue with $400K EBITDA might sell for $1.6M to an individual buyer (4x) or $4.8M to a consolidator (12x). Same practice, 3x price difference. The key question is: does your practice qualify for the corporate market?

What Corporate Buyers Actually Screen For

Having represented practices in conversations with NVA, Mars, and several PE-backed platforms, I can tell you exactly what their acquisition teams evaluate:

Collections of $1.5M+ annually. Most consolidators have minimum revenue thresholds. Below $1.5M, the overhead of integrating the practice doesn't justify the management attention. Some will go as low as $1M if the practice is in a strategically important market or adjacent to an existing location, but $1.5M-$2M is the real floor for competitive bidding.

EBITDA margins of 15%+. After normalizing for owner compensation (replacing actual owner draw with a market-rate DVM salary of $150K-$180K), the practice needs to generate meaningful EBITDA. Corporate buyers can improve margins by 3-5 percentage points through group purchasing, shared services, and revenue optimization — but they need a viable starting point.

Multi-DVM structure. Single-doctor practices are the hardest to sell at premium multiples. If you are the only veterinarian and you leave, the buyer has to immediately find a replacement — or the practice generates zero revenue. Practices with 2-3+ DVMs, especially with an associate who could become medical director post-close, command significantly higher multiples.

Revenue diversity. Consolidators look at the breakdown between wellness/preventive care, medical/diagnostic, surgical, dental, and boarding/ grooming. Practices with strong wellness programs (vaccination protocols, preventive care plans) are preferred because wellness revenue is recurring and predictable. Over-reliance on surgical revenue is a concern because it's episodic and harder to forecast.

Active patient count and visit frequency. Corporate buyers want to see 1,500+ active patients (those who visited within the past 18 months) with 2.5+ visits per patient per year. High active patient counts with low visit frequency suggest untapped revenue potential — which some buyers view as upside and others view as a yellow flag about the practice's client engagement.

Collections-Based Valuation: The Vet-Specific Approach

Veterinary practices have a valuation shorthand that's unique to the industry: percentage of gross collections. This method values the practice at 60-100%+ of annual gross collections (revenue), depending on profitability and growth trajectory.

This approach exists because vet practice profitability is relatively standardized. A well-managed general practice should generate 18-22% EBITDA margins after normalizing owner compensation. So 80% of collections on a $2M practice ($1.6M) is roughly equivalent to 8-9x normalized EBITDA ($180K-$200K EBITDA range).

Where this breaks down: practices with unusually high or low margins. A practice doing $3M in collections with 25% EBITDA margins ($750K) is worth far more than 80% of collections ($2.4M) would suggest — it should price at 8-12x EBITDA ($6M-$9M). Conversely, a practice with bloated costs and 10% margins will struggle to achieve even 60% of collections.

I generally recommend running both the collections-based and EBITDA-based valuations and using the higher number as a starting point for negotiation. Corporate buyers will do their own EBITDA analysis regardless of how you present the number.

The Mars/NVA Dynamic and Why It Matters to You

Mars Veterinary Health is the elephant in every room. Through VCA (1,000+ hospitals), Banfield (1,000+ locations), BluePearl (100+ emergency/specialty hospitals), and direct acquisitions, Mars controls more veterinary revenue than any other entity. Their acquisition pace has slowed from peak levels but remains substantial.

NVA (National Veterinary Associates), backed by JAB Holding, operates 1,400+ locations globally and remains an aggressive acquirer. Pathway, Thrive, and newer entrants like Galaxy Vets and Mission Veterinary Partners round out the corporate buyer landscape.

What this competitive dynamic means for sellers:

• Multiple bidder scenarios are common. If your practice meets the corporate thresholds, you can expect interest from 3-5 consolidators simultaneously. Running a competitive process through an experienced veterinary M&A advisor typically yields 15-25% higher prices than negotiating with a single buyer.
• Deal structures vary significantly. Mars/VCA typically offers straightforward cash-at-close structures. PE-backed platforms may offer higher headline multiples but with 10-20% tied to earn-outs or seller notes. NVA has historically been known for offering equity rollover opportunities — you sell 70-80% now and retain 20-30% equity that participates in the next recapitalization.
• Post-close terms matter enormously. Most corporate buyers require the selling DVM to stay on for 1-3 years. Your employment agreement (salary, schedule, clinical autonomy) is as important as the purchase price. I've seen sellers accept a lower multiple in exchange for a guaranteed four-day workweek and no weekend shifts.

Associate Retention: The Deal Killer No One Talks About Enough

The veterinary labor shortage is severe. The AVMA estimates a shortfall of 15,000+ veterinarians by 2030. New graduates carry average student debt of $180K+ and can command starting salaries of $110K-$130K in most markets, up to $150K+ in competitive urban areas.

Why this matters for your valuation: if your associate DVMs leave after the sale, the buyer just paid millions for a practice that can't see patients. Every corporate buyer's diligence process now includes associate interviews (with your permission) to gauge retention likelihood.

Factors that affect associate retention risk:

• Compensation structure. Associates on ProSal (base salary plus production percentage, typically 20-22% of production above a threshold) are more aligned with practice performance than those on straight salary. Buyers prefer ProSal because it incentivizes productivity.
• Schedule and work-life balance. The newest generation of DVMs prioritizes flexibility. Practices that already offer four-day weeks, limited emergency coverage, and reasonable appointment volumes (18-22 patients/day, not 30+) retain associates better.
• Non-compete agreements. Enforceable non-competes (which vary dramatically by state — California bans them entirely, while most Southern states enforce them) provide some protection. But a non-compete only prevents an associate from competing locally; it doesn't prevent them from relocating.
• Practice culture. This sounds soft, but it's real. Practices with high associate satisfaction, good support staff ratios (3+ techs per DVM), modern equipment, and collaborative clinical environments retain associates through ownership transitions far better than practices that run associates into the ground.

I recommend that any selling DVM have candid conversations with their associates before going to market — not necessarily disclosing the sale, but understanding their career plans and ensuring compensation is competitive. Discovering during diligence that your associate of 8 years plans to leave in 6 months is a fast way to kill a deal.

Specialty and Emergency: A Different Valuation Universe

Everything above applies to general practice. Specialty and emergency veterinary hospitals operate in a different market with different economics.

Emergency hospitals with 24/7 coverage command the highest multiples in veterinary medicine — often 12-18x EBITDA. The barriers to entry are enormous (specialized equipment, credentialed specialists, 24-hour staffing), referral relationships take years to build, and revenue per patient visit is 5-10x higher than general practice. BluePearl (Mars) and Ethos Veterinary Health are the most active acquirers in this segment.

Specialty-only practices (dermatology, oncology, ophthalmology, surgery) typically trade at 10-14x EBITDA when they have established referral networks and board-certified specialists with long tenure.

The catch: these practices are highly dependent on individual specialists. A veterinary oncologist with a loyal referral network is extraordinarily difficult to replace. Buyers price this key-person risk heavily, and earn-out structures tied to specialist retention are common in these deals.

Practical Valuation Ranges by Practice Profile

Based on transaction data and current market conditions, here's where different practice profiles typically land:

• Solo practitioner, under $1M collections: 3-4x SDE ($300K-$600K total value). Buyer is typically another DVM. SBA financing is common.
• 1-2 DVM practice, $1M-$2M collections, average profitability: 5-7x EBITDA or 65-80% of collections. Mix of individual and smaller corporate buyers.
• Multi-DVM practice, $2M-$5M collections, strong margins and growth: 8-12x EBITDA or 80-100% of collections. Full corporate buyer competition likely.
• Large multi-location or specialty/emergency, $5M+ collections: 10-14x EBITDA. Premium corporate and PE buyer interest. Possible equity rollover structures.

Positioning Your Practice for Maximum Value

If you're considering selling within the next 2-3 years, focus on these value drivers:

Grow collections above $1.5M. This is the single most impactful threshold. Below it, you're selling to individuals at 4-5x. Above it, you're selling to corporations at 8-12x. Fee increases of 5-8% annually (which the market has absorbed without significant client attrition), additional appointment slots, and wellness plan enrollment all contribute.

Add a second DVM if you're solo. Even a part-time associate working 2-3 days per week transforms the practice from a key-person-dependent asset into one that can survive the owner's departure. The cost of an associate ($130K-$160K fully loaded) is dwarfed by the multiple expansion it enables.

Build wellness plan enrollment. Monthly wellness plans ($30-$60/ month covering annual exams, vaccinations, dental cleanings, and basic diagnostics) function as recurring revenue. A practice with 400+ wellness plan members has $200K-$300K in predictable annual revenue. Corporate buyers price this similarly to how PE firms price maintenance contracts in home services.

Invest in modern equipment. Digital radiography, in-house blood analyzers (Idexx or Abaxis), dental radiography, and ultrasound capability signal a practice that's been maintained. Buyers discount practices that need significant capital expenditure post-close.

Document everything. SOPs for common procedures, training manuals for support staff, inventory management protocols, client communication templates. Corporate buyers are integrating your practice into a system — the more documented your operations, the easier (and less risky) that integration.

The veterinary M&A market remains one of the most active in healthcare services. The corporate consolidation wavehas years of runway left, DVM shortages ensure high barriers to entry, and pet ownership trends (70% of U.S. households) support long-term revenue growth. If your practice meets the corporate buyer thresholds, you're in a strong negotiating position.